Allscripts offers buyouts to employees

Cara Livernois | | Health Exec | EMR/EHR

Allscripts, the Chicago-based electronic health record (EHR) company, has confirmed it is offering buyouts to employees, according to reporting from POLITICO.

Allscripts acquired Practice Fusion and portions of McKesson and NantHealth in the past year, so the buyouts could be part of an adjustment as new assets are settled. The company reported profitability over the last year, but interest rates evenly matched revenue growth.

According to Morning eHealth, former employees report the buyouts are widespread.

"As Allscripts continually looks to balance resources across the company to ensure we are best supporting clients, and as the company continues to realize expected synergies resulting from our recent acquisitions, Allscripts offered a Voluntary Early Retirement Program (VERP) to a limited number of eligible U.S.-based associates," a company spokeswoman said. Some of the “eligible associates have opted to take advantage of the offer."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Private equity-backed cardiology group puts cloud-based technology in hands of its cardiologists
AI helps cardiologists deliver personalized healthcare—but there is still plenty of work to do
Indiana hospitals reduce nuisance alerts by 77% with medication decision support software
Leveraging machine learning to rapidly create clinical AI algorithms
How medication reconciliation data consolidation in the EHR enables better patient care
How are the best in KLAS Health IT vendor rankings created?

Around the web

AI in Healthcare
4 points crucial to the nimble regulation of GenAI

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Design by Adaptive Theme
Trimed Popup
Trimed Popup